Convatec

01-Jul-25

Corporate

Continence Care

Ostomy Care

Comment on CMS proposed rule change issued 30 June 2025

Convatec notes the Centers for Medicare & Medicaid Services (CMS) proposed rule published on 30 June 2025

26-Jun-25

Corporate

Infusion Care

Convatec welcomes regulatory approval of subcutaneous apomorphine infusion f...

Convatec’s Neria™ Guard infusion set is used for continuous subcutaneous infusion of a wide range of pharmaceuticals ...

22-May-25

Corporate

Financial Performance

AGM trading update for the four months ended 30 April 2025

Strong start to the year, on track to deliver targets

26-Jan-25

Corporate

Advanced Wound Care

Convatec welcomes the postponement of Local Coverage Determinations (LCDs) on...

Healthcare professionals (HCPs) and patients have reported significant clinical benefits from the use of InnovaMatrix®.

20-May-25

Corporate

Infusion Care

Advancing subcutaneous infusion therapy for patients through innovation and p...

More than one million people around the world rely on Convatec infusion sets every day

25-Apr-25

Corporate

Advanced Wound Care

Convatec receives regulatory approval for ConvaNiox™

New solution set to improve patient outcomes for hard to heal wounds

11-Apr-25

Corporate

Advanced Wound Care

Convatec welcomes postponement of Local Coverage Determinations (LCDs) on ski...

Medicare patients in the US, supported by healthcare professionals (HCPs), will continue to benefit from InnovaMatrix®.

31-Mar-25

Corporate

Ostomy Care

Convatec announces exclusive collaboration with largest Wound, Ostomy and Con...

Unique global programme and collaboration with Wound, Ostomy, and Continence Nurses Society™ (WOCN®)

18-Mar-25

Corporate

Advanced Wound Care

Convatec showcases its strongest wound care innovation pipeline ever at EWMA

Convatec will highlight key findings and the latest developments designed to deliver better healing outcomes

26-Feb-25

Corporate

Financial Performance

Annual results for the year ended 31 December 2024

Operational and strategic delivery drives double-digit adjusted EPS and cashflow growth